ASCENT is a 12-month, multi-country, multi-centre, prospective, non-comparative and
non-interventional (observational), post-reimbursement real-world evidence study that will
assess asthma symptom control, lung function, and PROs including HRQoL after tezepelumab treatment initiation in participants with severe asthma in Europe and Canada. The overall aim of this study is to complement evidence obtained from randomised controlled trials and
provide new data focusing on the holistic and patient-centred outcomes of treatment (PIO).